# US 2026/0110699 A1 · Astrocyte traumatome and neurotrauma biomarkers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0110699 A1
- Document ID: US20260110699A1
- Status: Published application
- Kind: A1
- Application number: 19/197,759
- Filed: 2025-05-02
- Published: 2026-04-23
- Earliest claimed: 2015-05-05
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: Ina-Beate WANNER; Joseph A. LOO
- Web page: https://patentgrep.com/patent/US20260110699A1

## CPC

- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 33/577: involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- C12Y 201/01259: [Fructose-bisphosphate aldolase]-lysine N-methyltransferase (2.1.1.259)
- G01N 2800/2871: Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
- G01N 2800/40: Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Y: ENZYMES

## Abstract

A method for detection or monitoring status of traumatic brain injury (TBI) and/or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP/FABP7), or a trauma-specific break down product (BDP) of ALDOC or BLBP/FABP7. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. Optionally, the method further comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB/HSP27), a trauma-specific proteolytic cleavage product of ALDOC, GS, PEA15, or CRYAB, or any combination of two or more thereof.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A method for detection and treatment of neurotrauma in a subject, the method comprising:
(a) contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of neurotrauma, wherein the marker of neurotrauma comprises brain lipid binding protein (BLBP/FABP7), or a trauma-specific break down product (BDP) of BLBP/FABP7,
(b) measuring the amount of marker present in the specimen as compared to a control sample;
(c) determining the presence of an elevated amount of the marker in the specimen compared to the control sample; and
(d) treating the subject for neurotrauma when the specimen is determined to have an elevated amount of the marker.

### Claim 31 (depends on 30)

The method of claim 30, wherein the BDP of BLBP/FABP7 comprises a 20-30 kDa fragment, or the marker of neurotrauma further comprises aldolase C (ALDOC), or a trauma-specific break down product (BDP) of ALDOC, wherein the trauma-specific BDP of ALDOC is selected from the group consisting of a 38 kDa fragment, a 35 kDa fragment, a 30 kDa fragment, and a 23 kDa fragment.

### Claim 32 (depends on 30)

The method of claim 30, further comprising measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB/HSP27), a trauma-specific proteolytic cleavage product of GS, PEA15, or CRYAB, or any combination of two or more thereof, wherein the trauma-specific proteolytic cleavage product of GS is selected from the group consisting of a 37+35 kDa doublet, a 32 kDa fragment, a 23 kDa fragment, a 20 kDa fragment, and 18 kDa fragment; the trauma-specific proteolytic cleavage product of PEA15 is selected from the group consisting of a 12+13 kDa doublet and an 8 kDa fragment; and the trauma-specific proteolytic cleavage product of αB-crystallin is selected from the group consisting of an 18+19 kDa doublet, a 17 kDa fragment, a 15+14 kDa doublet and a 8 kDa fragment.

### Claim 33 (depends on 30)

The method of claim 30, further comprising measuring the amount of apolipoprotein B (APOB) in a cerebrospinal fluid (CSF) sample obtained from the subject.

### Claim 34 (depends on 30)

The method of claim 30, further comprising measuring the amount of glial fibrillary acid protein (GFAP) or a 20-30 kDa trauma-specific break down product (BDP) of GFAP.

### Claim 35 (depends on 30)

The method of claim 30, wherein the reagents of step (a) comprise antibodies that specifically bind the marker of neurotrauma, and the measuring comprises immunoassay, and the immunoassay comprises western blotting, immunofluorescence, immunoluminescence, radioimmunoassay, or enzyme linked immuno-sorbent assay (ELISA).

### Claim 36 (depends on 30)

The method of claim 30, wherein the control sample is a pre-injury sample obtained from the subject or an average value obtained from a control cohort of healthy subjects.

### Claim 37 (depends on 30)

The method of claim 30, wherein the neurotrauma comprises traumatic brain injury (TBI), mild TBI (concussion) and/or traumatic spinal cord injury (SCI).

### Claim 38 (depends on 37)

The method of claim 37, wherein measuring the amount of the marker of neurotrauma distinguishes TBI from a chronic neurodegenerative disease.

### Claim 39 (depends on 30)

The method of claim 30, wherein the specimen of bodily fluid comprises plasma, serum, cerebrospinal fluid (CSF), nasal fluid, cerumen, urine, saliva, lacrimal tears, or brain microdialysate.

### Claim 40 (depends on 30)

The method of claim 30, wherein the reagents comprise protein-sequence and -fragment-specific peptides and the measuring comprises targeted quantitative mass spectrometry, or the measuring comprises multiple or parallel reaction monitoring mass spectrometry.

### Claim 41 (depends on 30)

The method of claim 30, wherein the subject has had a suspected injury, and the measuring is performed within 24 hours of a suspected injury to the subject or within one week of a suspected injury to the subject.

### Claim 42

A method for monitoring treatment of neurotrauma in a subject, the method comprising:
(a) assaying a specimen of bodily fluid obtained from the subject being treated for neurotrauma for a marker of neurotrauma, wherein the marker of neurotrauma comprises brain lipid binding protein (BLBP/FABP7) or a trauma-specific break down product (BDP) of BLBP/FABP7 thereof;
(b) measuring the amount of marker present in the specimen as compared to a control sample; and
(c) determining the presence of an elevated amount of the marker in the specimen compared to the control sample, thereby detecting progression of neurotrauma in the subject; and
(d) re-initiating or increasing treatment for neurotrauma when the specimen is determined to have an elevated amount of the marker.

### Claim 43 (depends on 42)

The method of claim 42, wherein the BDP of BLBP/FABP7 comprises a 20-30 kDa fragment, or the marker of neurotrauma further comprises aldolase C (ALDOC), or a trauma-specific break down product (BDP) of ALDOC, wherein the trauma-specific BDP of ALDOC is selected from the group consisting of a 38 kDa fragment, a 35 kDa fragment, a 30 kDa fragment, and a 23 kDa fragment.

### Claim 44 (depends on 42)

The method of claim 42, further comprising measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB/HSP27), a trauma-specific proteolytic cleavage product of GS, PEA15, or CRYAB, or any combination of two or more thereof, wherein the trauma-specific proteolytic cleavage product of GS is selected from the group consisting of a 37+35 kDa doublet, a 32 kDa fragment, a 23 kDa fragment, a 20 kDa fragment, and 18 kDa fragment; the trauma-specific proteolytic cleavage product of PEA15 is selected from the group consisting of a 12+13 kDa doublet and an 8 kDa fragment; and the trauma-specific proteolytic cleavage product of αB-crystallin is selected from the group consisting of an 18+19 kDa doublet, a 17 kDa fragment, a 15+14 kDa doublet and a 8 kDa fragment.

### Claim 45 (depends on 42)

The method of claim 42, further comprising measuring the amount of apolipoprotein B (APOB) in a cerebrospinal fluid (CSF) sample obtained from the subject.

### Claim 46 (depends on 42)

The method of claim 42, further comprising measuring the amount of glial fibrillary acid protein (GFAP) or a 20-30 kDa trauma-specific break down product (BDP) of GFAP.

### Claim 47 (depends on 42)

The method of claim 42, wherein the measuring comprises immunoassay, and the immunoassay comprises western blotting, immunofluorescence, immunoluminescence, radioimmunoassay, or enzyme linked immuno-sorbent assay (ELISA).

### Claim 48 (depends on 44)

The method of claim 44, wherein the control sample is a pre-injury sample obtained from the subject or an average value obtained from a control cohort of healthy subjects.

### Claim 49 (depends on 44)

The method of claim 44, wherein the neurotrauma comprises traumatic brain injury (TBI), mild TBI (concussion) and/or traumatic spinal cord injury (SCI) control sample is.

### Claim 50 (depends on 49)

The method of claim 49, measuring the amount of the marker of neurotrauma distinguishes TBI from a chronic neurodegenerative disease.
